Korean J Physiol Pharmacol 2022; 26(3): 207-218
Published online May 1, 2022 https://doi.org/10.4196/kjpp.2022.26.3.207
Copyright © Korean J Physiol Pharmacol.
Suhan Cho1,#, Hojun Lee2,#, Ho-Young Lee3, Sung Joon Kim1,4,*, and Wook Song5,6,7,*
1Department of Physiology, Seoul National University College of Medicine, Seoul 03080, 2Department of Sport and Exercise Science, Seoul Women's University, Seoul 01797, 3Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam 13620, 4Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul 03080, 5Health and Exercise Science Laboratory, Institute of Sport Science, 6Department of Physical Education, 7Institute on Aging, Seoul National University, Seoul 08826, Korea
Correspondence to:Sung Joon Kim
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Aging in mammals, including humans, is accompanied by loss of bone and muscular function and mass, characterized by osteoporosis and sarcopenia. Although resistance exercise training (RET) is considered an effective intervention, its effect is blunted in some elderly individuals. Fibroblast growth factor (FGF) and its receptor, FGFR, can modulate bone and muscle quality during aging and physical performance. To elucidate this possibility, the FGFR inhibitor NVP-BGJ398 was administrated to C57BL/6n mice for 8 weeks with or without RET. Treatment with NVP-BGJ398 decreased grip strength, muscular endurance, running capacity and bone quality in the mice. FGFR inhibition elevated bone resorption and relevant gene expression, indicating altered bone formation and resorption. RET attenuated tibial bone resorption, accompanied by changes in the expression of relevant genes. However, RET did not overcome the detrimental effect of NVP-BGJ398 on muscular function. Taken together, these findings provide evidence that FGFR signaling may have a potential role in the maintenance of physical performance and quality of bone and muscles.
Keywords: Atrophy, Bone density, Exercise training, Fibroblast growth factor receptor, Muscle
The ability to maintain bone and skeletal muscle quality is important for leading a long, healthy life. Bone and muscle mass and function are well-known predictors of health outcomes, such as the risk bone of fracture, osteoporosis, sarcopenia, and other muscular dystrophic diseases [1-4]. Of many musculoskeletal dysfunctions, sarcopenia, the aging-related loss of muscular strength and mass is well known and is correlated with loss of bone density . Osteoporosis is characterized by an excessive loss of bone density . Aging-related decreases in muscle and bone mass are accompanied by altered cellular conditions and increased inflammatory conditions [7-9]. Sarcopenia and osteoporosis share physical  and biochemical pathophysiological mechanisms .
Resistance exercise training (RET) is an effective measure to counter the functional loss of bone and muscle during aging . However, previous studies have demonstrated that some individuals show blunted gain from training adaptation in terms of muscle mass and strength , and prevention of bone loss [14,15].
Fibroblast growth factor (FGF) and its receptor, FGFR, can modulate muscle and bone quality because FGF2 has the potential to enhance bone formation
Therefore, our aim in this study was to investigate the role of FGFR signaling in physical performance using an FGFR antagonist NVP-BGJ398. Furthermore, we evaluated the role of FGFR signaling during 8 weeks of RET and demonstrated that inhibition of this signaling reduced muscle and bone quality, leading to decreased physical performance in mice, which was partly overcome by the 8 weeks of RET.
C57BL/6n mice (male, 8–9 weeks old) were purchased from Orient Bio Inc. (Stock name: C57BL/6NCrljBgi; Orient Bio Inc., Seongnam, Korea), and were managed under the principles established by the college of veterinary medicine animal laboratory in Seoul National University (SNU). The mice were kept at 22°C, 40%–50% humidity and on a 12:12-h light-dark cycle, fed with Rodent chow 5057 (Purina Korea, Seoul, Korea). The food intake was recorded in consequence day. All experimental methods were approved by the SNU Institutional Animal Care and Use Committees. The certification number was SNU-150820-4-6.
The animals were randomly assigned to each of the following groups: inhibition control group (Inh) and sham control group (Sham). At least 6–7 mice were conducted with experiment for each group. FGFR inhibitor NVP-BGJ398 (50 mg/kg body weight; Novartis, Basel, Switzerland) or sham (PEG-300/Glucose 5%, 2:1 mix) were administered by oral gavage as previously described . The treatment was conducted three times per week, throughout the 8 weeks of experimental period.
The only encouragement was a gentle finger tapping on the animal’s tail. When the rodents reached the top of the ladder, they were allowed to rest for 1–2 min. After the rest period, additional 3 g was added on the previous weight, and the rodents were returned to the bottom of the ladder for the next session. If any mice were not able to climb with the attached load, one additional minute was given for further rest then placed at the bottom of ladder. This procedure was repeated until ten climbs were achieved. Every initial load was set at 50% of the maximal weight lifted of previous exercise training.
Grip strength test was measured to illustrate the maximal force of grasping object and it is known to represent the strength of an individual. Animals were allowed to grasp a grid which is attached to the force gauge and pulled until they became completely detached from the grid. The force was recorded for three times with at least two minutes of rest between every trial of measurement. Only maximum force record was taken for the further analysis. The grip strength was measured with a grip strength meter (Model GS3; Bioseb, Chaville, France), and measurement method was adopted and modified from the one which was reported previously . The grip strength was measured weekly, after 24–48 h of the last exercise trial of the week. The animal grasped the steel grid with its four-limb, then its tail was gently pulled with the experimenter’s fingers. Maximum force (g) was measured and recorded on the instrument.
Hanging time was measured to represent the muscular endurance capacity of a mouse. Animals were allowed to familiarize to the grid at least 1 min prior to the actual test. Every rodent conducted three trials and the maximum time was taken. Animal was placed on the 20 × 30 cm grid with 10 g weight attached on tail, and flipped over to measure the time until mouse falls. When the mouse fell within 10 sec, the animal was rested sufficiently and retested afterward. This was conducted 48 h after last intervention of 8th week of training.
Treadmill exhaustion test was performed to test endurance capacity of animal. Rodents were forced to run until complete exhaustion and time was measured for further analysis. For the analysis, Exer. 3/6 treadmill (Columbus Instruments, Columbus, OH, USA) was used and no incline was applied throughout the test. Mice were stimulated at the tail or posterior part of the body when they were reluctant to run. Mice were indicated to run for 5 min with 5 m/min and thereafter speed was increased by 1 m/min every minute until exhaustion. Exhaustion was defined when mice were unable to run although mice were continuously stimulated more than 15 sec.
Total RNA from mouse tissues and organ was extracted by using an RNA purification system (Introgen) following the manufacturer’s protocol. mRNA was reverse-transcribed using AccuPower CycleScript RT PreMix (Bioneer, Daejeon, Korea) and RT-PCR was performed using SYBR Green and an ABI StepOne Real Time PCR instrument (Applied Biosystems, Cheshire, UK). Target gene expression was normalized with the control gene (
Table 1 . Primers for Real-time PCR using SensiFAST SYBR Lo-ROX Mix protocol.
|Gene||Forward primer (5’-3’)||Reverse primer (3’-5’)|
Body composition was measured with Minispec live mice TD NMR analyzer (Bruker LF50, Ettlingen, Germany) . This was conducted without anesthetics, and live mice were placed into cylindrical tube and inserted to scan for less than two minutes. After the scan procedure, mice were anesthetized with isoflurane gas inhalation for sample collection.
Bone quality was measured with
Data organization and statistical analysis were performed using Microsoft Excel (Microsoft, Redmond, WA, USA) and SPSS 23.0 software (IBM Co., Armonk, NY, USA). All data were represented as mean ± SEM. Significant differences between two groups were determined using two-tailed Student’s t-test. p-values lower than 0.05 were considered they were significantly difference.
Oral administration of the FGFR inhibitor NVP-BGJ398 (50 mg/kg/day) for 8 weeks did not induce significant differences in body weight (b.w.) between the vehicle-treated sham and inhibitor-treated (Inh) groups (Fig. 1A). Nevertheless, there was a tendency of a lower ∆b.w. in the Inh group than in the sham group (3.7 ± 0.45 g
To elaborate on the effects of FGFR inhibition on physical performance in the mice, we conducted grip strength, hang time, and exhaustion tests 48 h after the final treatment with either NVP-BGJ398 or vehicle control. Decreased grip strength was demonstrated in the Inh mice compared to that in the sham group (172.9 ± 5.34 g
Since a close relationship exists between changes in grip strength and bone density [30,31], we further examined bone density and metabolic activity to understand the decrease in physical performance during FGFR signaling inhibition. The micro/PET CT
To explain the attenuated bone quality from micro-CT and NaF18-PET/CT scan data, we examined the expression of genes related to bone formation and resorption. The Osteocalcin (
Limb skeletal muscle mass is a major factor that contributes to physical performance. The weights of the soleus, gastrocnemius, tibialis anterior and extensor digitorum longus were normalized to b.w. and compared between the sham and Inh groups. However, the summarized results did not show any differences between the two groups (Fig. 3A). To assess the muscle quality, grip strength was adjusted based on the total mass of lower limb skeletal muscle. There was clear decrease in muscle quality with FGFR inhibition (Fig. 3B).
To assess the changes in muscle quality, we analyzed muscle mRNA expression using RT-qPCR. Gene expression levels of the gastrocnemius muscle were normalized to
As expected, RET increased grip strength, adjusted the muscle wet weight of the hind limb, and hanging time in the sham mice (Supplementary Fig. 1). We. then investigated the effects of RET on growth over 8 weeks and physical performance in the Inh mice. Growth, that is, the tendency of b.w. gain, did not show any significant differences between the RET-combined sham and Inh groups. However, the body composition analysis revealed that the extent of decreased lean body mass and body fat percentages were attenuated with RET intervention; there was no significant difference in the two parameters between the two groups (Fig. 4C, D).
Contrary to the beneficial effect of RET on the physical performance of normal mice, the lower performance in the Inh group could not recover to the level of the sham group after 8 weeks of RET (Fig. 4E–G).
To investigate the effects of RET on reduced bone quality by FGFR inhibition, micro-CT and NaF18-PET/CT scan analyses were conducted 48 h after the final intervention. Eight weeks of RET failed to restore the decreased bone mineral density (Fig. 5A), however, the bone turnover rate was rescued, as the averaged SUV did not differ between the sham and Inh groups combined with RET (sham + RET and Inh + RET, respectively, Fig. 5B). We further examined changes in gene expression related to bone formation and resorption. Consistent with the findings from the comparable bone metabolism between the sham + RET and Inh + RET groups (Fig. 5B), there was no difference in gene expression levels of
Similar to the findings of FGFR inhibition during normal growth, FGFR inhibition did not alter the changes in the lower limb skeletal muscle groups (Fig. 6A). Although the mRNA levels of atrophy markers were similar between the sham + RET and Inh + RET groups (Fig. 6C), this did not result in an improvement in muscle quality (Fig. 6B).
Our findings with the FGFR inhibitor NVP-BGJ398 in mice were characterized by reduced muscle strength and bone quality, while the mass of limb muscle was not affected. Decreased bone density is accompanied by reduced bone metabolism and decreased expression of osteogenic/osteoclastogenic genes. When the osteogenic process is increased, the gene expression ratio Rank:Opg in the tibia bone  represents the osteoclastogenic activity. Eight weeks of RET combined with NVP-BGJ398 (Inh + RET) failed to recover muscle strength and bone density in the mice, whereas no differences were observed in the bone metabolism rate and relevant genetic expression compared to sham + RET mice (Fig. 7).
Although statistically insignificant, the b.w. at week 8 of the experimental protocol was lower in the Inh group than that in the Sham group (p = 0.09). In addition, the comparison of body composition normalized to the b.w. (% lean body mass and % body fat) showed significantly lower values in the Inh group than in the sham group (Fig. 1C, D). Interestingly, the parameters of body composition in the Inh + RET group were not different from those in the sham + RET group (Fig. 4C, D). Taken together, RET was effective in the maintenance and recovery of body composition and bone metabolism under chronic inhibition of FGFR signaling, whereas functional impairment of muscle endurance could not be prevented.
Interestingly, changes in atrophy-related genes were observed in the muscle. Increased atrophic marker genes are associated with loss of muscle mass, strength, and function [33-35]. Although the limb muscle weights were not decreased in the Inh group, the
The 8 weeks of RET was effective in improving lower limb muscle mass and function (Supplementary Fig. 1). However, the Inh + RET group did not show recovery of grip strength and hang time when compared with the Inh group (Fig. 4E–G). In some previous studies with aged individuals, RET effects were blunted, and this phenomenon was explained by either decreased ribosomal biogenesis or long-term depression of muscle protein synthesis due to impairment in growth factor responses [36,37]. It was reported that a longer period (12 weeks) of RET showed significantly greater muscle quality in young individuals than in those who were older , and a similar observation was also found when training was conducted with older human groups (> 70 years) . In addition, RET-induced hypertrophy of the plantaris muscle was less prominent in old mice than in young mice, and a microarray study showed relevant changes of ELF2 and mTOR signaling . This evidence may partially explain the effects of blunted RET adaptation on muscle quality. However, to provide a proper explanation of skeletal muscle function, other factors (neuromuscular adaptation, muscular metabolism, and environmental condition) should be considered, which were not in the present study.
Notably, the decreased bone density due to FGFR inhibition was maintained, whereas the increased bone resorption was restored by RET (Fig. 5A, B). Previous reports have shown that b.w. and muscle strength are not always correlated with each other, whereas bone mineral density and muscle strength are highly correlated [39,40]. The present study also showed a decrease in grip strength and bone loss with upregulated osteoclastogenic genes in the Inh group (Fig. 3). However, the beneficial effects of RET in the Inh group were limited to bone metabolism without the recovery of muscle strength.
FGFR signaling is important for bone formation, and inhibition of FGFR can lead to growth retardation . When FGFR1 and FGFR2 are conditionally mutated or knocked out, humans and mice exhibited skeletal growth abnormality [42,43]. Furthermore, FGF2 knockout mice demonstrated neuronal defect, reduced blood pressure, and other abnormal phenotypes . FGF/FGFR signaling has been reported to control osteoblast activity by enhancing ERK1/2 signaling . Therefore, it is not surprising that the pharmacological inhibition of FGFR affects bone density. However, the unaltered limb muscle weight and negligible effect on total b.w. were unexpected findings. We cautiously interpret these results to suggest that the amount and duration of NVP-BGJ398 treatment may have been insufficient for the full
Increased bone turnover due to RET has been reported . Mechanostat theory states mechanical loading transmits stimuli to osteoblasts and osteoclasts, which are involves in bone formation and resorption [47-49]. Furthermore, recent evidence suggests that not only does mechanical stress acts on bone formation, but also that some myokines can be effective in enhancing bone quality . Skeletal muscle secretes various growth factors including insulin-like growth factor 1 (IGF-1), FGF2 and FGF21. IGF-1 and FGF2 enhance bone formation
In conclusion, our data revealed a potential role for FGFR signaling in physical performance related to muscle and bone function. Physical performance is important for quality of life and declines during aging process. Thus, the decrease in FGFR signaling may be related to the aging-dependent loss of physical performance. Furthermore, RET adaptation could be blunted by FGFR signaling inhibition, which may partially explain training adaptation during aging process. However, further analysis is required to clarify this relationship. As NVP-BGJ398 is not a specific inhibitor for certain FGFRs, and the presence of FGFR and FGF families is ubiquitous in whole organs in the body, specific knockout model may be required to test whether local inhibition changes whole body physiology.
Supplementary data including one figure can be found with this article online at https://doi.org/10.4196/kjpp.2022.26.3.207.kjpp-26-3-207-supple.pdf
This work was supported by the National Research Foundation of Korea funded by the Ministry of Science, ICT, and Future Planning (NRF-2013M3A9B6046417, NRF-2021R1A2C2007243, Korea Mouse Phenotyping Project NRF-2013M3A9D5072550, 2013M3A9D5072560 and MEST 2011-030135), and by the Ministry of Education (NRF-2014R1A1A2058645).
The authors declare no conflicts of interest.
|View Full Text||Article as PDF|
|Abstract||Figure & Table|
|Print this Page||Export to Citation|
ⓒ 2019. The Korean Journal of Physiology & Pharmacology. Powered by INFOrang Co., Ltd